The Future of  Skin Cancer Detection

Meet DermaSensor: a non-invasive, AI-powered device that provides an immediate, objective result for skin cancer risk.

50% Off for the First 3 Months – Now $199/Month (Regularly $399 for Unlimited Users & Patients)

96% sensitivity for detecting all three  common skin cancers ¹

Proprietary, FDA-cleared algorithm provides  instant results

First FDA device cleared for primary care use

Hassle-Free Returns After 90 Days

“With integrating DermaSensor’s innovative technology into our practice, we can now offer enhanced skin cancer assessment capabilities right in our community, ensuring timely referrals for our patients.”

As Featured In

Bridging the Gap in Skin Cancer Detection: Innovative Solutions for Rapid Diagnosis

Skin cancer is a pervasive and underdiagnosed health concern in the United States, exacerbated by the inefficiencies within the healthcare system. Primary care physicians, who are on the frontline to appropriately treat and triage a host of conditions, have had a lack of adequate diagnostic aids to assess skin lesions. There is an unmet need for tools to improve identification of lesions requiring referral, which may otherwise lead to delayed or missed detection of skin cancer.

Play Video

Key Features

96% sensitivity for detection across all three common skin cancers¹

Proprietary algorithm yields instant assessment.

Ergonomically designed, wireless, and easy to grip.

Always on, ensuring readiness when needed.

How it Works?

Identify lesions suggestive of skin cancer on the patient

Apply handheld DermaSensor device to the lesion and initiate first recording

Five spectral recordings are taken from the skin lesion to complete one scan

DermaSensor's algorithm analyzes spectral data and delivers assessment in seconds

Hassle-Free Returns

Hassle-free returns after 90 days.
 Month-to-Month & no restocking fees.

FDA Cleared

Immediate, objective result
for skin cancer risk

Cloud Integration

Save all of your data
on Cloud storage

96% Accurate

Detection rate across all
common skin cancers ¹

Technology

DermaSensor’s tip reflects and records quick bursts of light off the lesion’s cellular and sub-cellular content.

The light is analyzed by the built-in computer to provide information to help physicians assess skin lesions (including melanomas, squamous cell carcinomas, and basal cell carcinomas) to aid in a referral decision.

By examining the difference in light scattering, DermaSensor determines if the skin lesion output is “Monitor” or “Investigate Further,” with the latter result including a 1-10 confidence score for malignancy likelihood.

Elastic Scattering Spectroscopy (ESS) has been validated in 30+ publications on clinical studies for various cancer types. Many studies have shown ESS to provide information that is comparable to histopathologic assessment in the analysis of cellular microscopic structure.

Discover what other practitioners are saying.

At Sanctum Med + Wellness, we deliver exceptional healthcare services prioritizing patient well-being and addressing every aspect of their health. Adding the DermaSensor device to our comprehensive range of services further underscores our commitment to staying at the forefront of medical innovation.

Dr. Jessica Shepherd, MD, MBA, FACOG

Renowned Gynecologist and Good Morning America Media Personality

I am super excited to announce that we have a new device called DermaSensor at Montgomery Medical. I originally had the opportunity to work with DermaSensor through a clinical trial at Frontier Clinical Research. Now that it is FDA-cleared, we are excited to be one of the first PCP offices to offer this new technology that uses light to help us assess suspicious skin lesions. It is painless and only takes a few seconds to give us an immediate result.

Dr. Marcy Goisse, M.D.

Montgomery Medical

In sunny Miami, skin cancer is a real concern. I’m excited to elevate my practice with a new non-invasive, point-of-care skin cancer detection device! With its FDA-cleared, AI-powered technology, I can enhance detection accuracy and confidence, providing peace of mind and appropriate referrals for patients at high risk.

Dr. Eduardo Alarcon

IRT Medical

© 2024 DermaSensor, Inc. All Rights Reserved.
*Applies to $399 monthly subscription rate only (unlimited users and patients).
Please read the Legal Notice for further details.
View device indications for use, warnings, and precautions (no known contraindications).
Clinical Evidence Available Upon Request

80.0009.4

The Future of Skin Cancer Detection